Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the pharmacokinetics of Zavesca (miglustat,
OGT918) when given as single and multiple doses in juvenile patients with GM2 gangliosidosis.